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Background: Conventional placement of a wireless esophageal pH monitoring device in the 
esophagus requires initial endoscopy to determine the distance to the gastroesophageal junction. 
Blind placement of the capsule by the Bravo delivery system is followed by repeat endoscopy 
to confirm placement. Alternatively, the capsule can be placed under direct vision during 
endoscopy. Currently there are no published data comparing the efficiency of one method over 
the other. The objective of this study was to compare the method of Bravo wireless pH device 
placement under direct visualization with the conventional method.
Methods: A retrospective study involving 58 patients (29 patients with indirect and 29 patients 
with direct visualization) who had Bravo capsule placement. The physician endoscopy 
procedure notes, nurse’s notes, postprocedure notes, recovery notes, and pH monitoring results 
were reviewed. The safety of the procedures, length of the procedures, and patient tolerability 
were evaluated.
Results: None of the 58 patients had early detachment of the device and had no immediate 
procedure-related complications. The overall incidence of complications in both the groups was 
similar. No failures due to the technique were noted in either group. Average amount of time 
taken for the procedure was similar in both groups.
Conclusion: The technique of placing a Bravo pH device under direct visualization is as safe 
and effective as the conventional method. In addition, there is an added advantage of avoiding 
a second endoscopic intubation in the direct visualization technique.
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Introduction
Esophageal pH monitoring is an essential investigation in patients with suspected 
gastroesophageal reflux disease (GERD) with refractory symptoms and in patients who 
are considered for antireflux surgery in the absence of endoscopic changes of GERD.1 
It is also utilized for evaluation of patients with extraesophageal manifestations of 
GERD. Esophageal pH monitoring was traditionally performed by passing a catheter 
with a pH electrode transnasally and positioning the electrode 5 cm above the upper 
border of the lower esophageal sphincter. There were several drawbacks with the 
conventional method of testing, which include nose and throat discomfort, dysphagia, 
and nasal discharge, as a result of the catheter passing through the nose and throat into 
the lower esophagus. In the majority of cases, the patient is unable to perform daily 
activities with these catheters in place.2 Furthermore, the pH probe could potentially 
become displaced with changing body position, talking, or swallowing, which could 
alter the study results.3Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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In recent years, the traditional approach of catheter-based 
pH monitoring has been replaced by the wireless pH 
monitor, ie, the Bravo™ pH testing system (Medtronic Inc., 
Shoreview, MN). In this system, the Bravo capsule is placed 
into the esophagus with the assistance of the Bravo delivery 
system. The conventional (“indirect”) method of placing the 
capsule in the esophagus involves an initial endoscopy to 
determine the distance from the incisor teeth to the gastroe-
sophageal (GE) junction. The endoscope is then removed and 
the device is placed blindly using the Bravo delivery system 
as per the measurements obtained by endoscopy. After place-
ment of the Bravo capsule, the endoscope is reinserted again 
to confirm its attachment and location. This conventional 
method is a blind technique and usually requires perform-
ing endoscopy twice to confirm the attachment and correct 
positioning of the capsule in the esophageal wall.4
Another technique that has been used for placing the 
Bravo capsule provides accurate positioning and con-
firms attachment of the capsule under direct endoscopic 
visualization. In this technique (“direct” method), the Bravo 
delivery system is concurrently placed without removing the 
endoscope and the device is released at a desired location.5
Endoscopists have their own arbitrary preference for 
a particular technique of placing a device. There are no 
studies to compare the two methods of placing the device 
in terms of safety, patient tolerability, and reliability of the 
technique. The objective of this study was to compare the 
safety, performance, and tolerability of the technique of 
Bravo wireless pH device placement under direct endoscopic 
visualization (direct) with that of the conventional (indirect) 
technique of capsule placement.
Methods
After approval by the institutional review board, all patients 
who had the Bravo capsule placed in the esophagus by either 
direct visualization or the indirect conventional method were 
identified. From this patient population, 29 consecutive 
patients had the Bravo device placed by the direct method 
over a period of six months, when the endoscopists switched 
from their practice of placing a device from the indirect to 
the direct technique. In the control group, 29 patients who 
had the Bravo device placed by the indirect method were 
randomly selected. The physician endoscopy procedure 
notes, nurse’s notes, postprocedure notes, recovery notes, 
and patient questionnaire were all reviewed. Data on pH 
results, complications during the procedure, symptoms, 
and complications during the data recording period, patient 
tolerability, and degree of satisfaction with the test in both 
groups were obtained. Data were also obtained on time 
taken in the procedure. We hypothesized that procedures 
performed in the evening might take longer than procedures 
performed in the morning, which could be related to the 
endoscopist’s fatigue towards the evenings. Therefore, in 
order to minimize the bias, we compared the procedure time 
of morning procedures and evening procedures.
In addition, data were also obtained on patient experience 
of the procedure, willingness to repeat the procedure if 
needed, and number of workdays off following the procedure. 
Patient experience with the procedure of capsule placement 
was graded as good, average, and bad, as recorded from the 
questionnaire given to patients. Patient satisfaction with 
the test was recorded using a Likert 10-point visual analog 
scale, with zero signifying very unsatisfactory and 10 very 
satisfactory. Values of 1–4 were graded as unsatisfactory, 
values from 5–8 as average, and values of 9 and 10 as very 
satisfactory. Endoscopists were questioned about their views 
on the complexity and overall experience with the procedure. 
Intravenous diazepam was used as a sedative in both the 
groups. The primary outcome of the study was to compare 
the safety of the two methods. The secondary outcomes 
were to evaluate any difference in the time of the procedure, 
patient tolerability, and operator experience with the two 
methods. In the direct method of Bravo capsule placement, 
upper endoscopy was performed to examine the esophagus, 
stomach, and duodenum, and to identify the squamocolumnar 
junction. Next, while keeping the endoscope in the esophagus 
and with the gastroesophageal (GE) junction in view, the 
Bravo delivery system was inserted orally and passed through 
the throat alongside the endoscope until it became visualized 
in the endoscopic field. The measurements on the endoscope 
and the delivery device were matched. The scope was then 
withdrawn to 8 cm above the GE junction and then, under 
direct view of the delivery system, the Bravo capsule was 
deployed 6 cm above the GE junction in the same way as it 
is done in the conventional technique.
In the conventional (indirect) method, upper endoscopy 
was performed similarly to examine the duodenum, stomach, 
and esophagus, and then the distance between the squamo-
columnar junction and the incisors was measured. The 
endoscope was then removed and the Bravo pH monitoring 
device was deployed blindly using the Bravo delivery system 
guided by the measurements obtained from endoscopy. After 
placement of the Bravo capsule, the endoscope was reinserted 
to confirm its attachment and location.Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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Statistical analysis
The t-test was used for analysis of the length of procedure 
time. For analysis of time taken in procedures performed 
before noon and procedures performed in the afternoon, 
one-way analysis of variance was used. Chi-square analysis 
was used to analyze all other data. Statistical significance 
was considered reached when the P value was ,0.05. The 
SPSS 16 (SPSS, Chicago, IL) was utilized for all statistical 
analysis.
Results
Fifty-eight patients who had Bravo capsule placement by 
either the direct or indirect method were included in the study. 
Table 1 shows the baseline characteristics of the patient popu-
lation in the two groups. All the procedures were performed by 
two endoscopists (ID and CF). Both endoscopists used either 
method to place the device. The two groups were similar in 
terms of age, gender, and underlying diseases. One patient 
in the direct group and four patients in the indirect group had 
previously undergone Nissen’s fundoplication. There were no 
early detachments of the device and no prolonged retention of 
the device in any patient in either group. One of the patients 
in the “indirect” group had an esophageal stricture and needed 
dilatation before placement of the Bravo capsule. This patient 
had also previously undergone Nissen’s fundoplication. Post-
procedural complications in the two groups are summarized in 
Table 2. Among the patients who developed chest pain after 
the procedure, chest pain was severe enough in two patients 
in the direct group to require patient observation for three and 
five hours, respectively, before discharge. One of the patients 
in the indirect group had three attempts at device insertion. 
The device failed to transmit signals soon after deployment 
in two patients in the indirect group and in one patient in 
the direct group. One patient each in both the direct group 
and indirect group had pH recording for only 12 hours and 
19 hours, respectively. Two patients in the indirect group and 
one patient in the direct group were scheduled for 24-hour 
monitoring only. All other patients had two-day monitoring. 
The average recording time in the two groups was similar 
(mean 22 hours 51 minutes versus 22 hours 39 minutes for 
the direct and indirect methods, respectively, on day 1, and 
20 hours 31 seconds and 18 hours and 10 seconds on day 2). 
The mean Demeester score on the first day of recording in 
the direct and indirect groups was 29.84 (standard deviation, 
35.51) and 29.9 (34.5), respectively. The Demeester score on 
the second day of recording was 16.23 (13.6) and 23.1 (33.15) 
for the direct and indirect groups, respectively. In terms of 
patient experience and satisfaction with the test, the differ-
ence between the two groups was not statistically significant 
(Table 3). The willingness to repeat the test (if needed) in 
the two groups was also statistically insignificant. An equal 
number of patients in the two groups required days off work 
after the procedure. There was no difference between the time 
taken for the procedure between the two groups (Table 4). 
In the view of the endoscopists, there was no difference in 
the procedure, except for the ease of placement with the 
direct method.
Table 1 Patient demographics and indication for ph monitoring
 Direct  
(n = 29)
Indirect  
(n = 29)
Mean age (years, range) 51 (26–80) 46 (27–87)
Sex (M:F) 9:20 8:21
indication for ph monitoring
intractable symptoms on PPi 14 (48%) 10 (34%)
Extraesophageal symptoms 14 (48%) 12 (41%)
Preoperative evaluation 0 (0%) 3 (10%)
reflux symptoms after  
nissen’s procedure
1 (3.5%) 4 (13.7%)
Abbreviations: PPi, proton pump inhibitor; M, male; F, female.
Table 3 Patient tolerability and experience
Characteristic Direct (%) Indirect (%) P value
Patient experience
Good 10 (34%) 8 (27%) 0.821
Okay 16 (55%) 17 (58%)
Bad 3 (10%) 4 (13%)
Satisfaction (score)
Good (9–10) 22 (76%) 18 (62%) 0.115
Average (5–8) 3 (10%) 4 (13%)
Bad (1–4) 4 (13%) 8 (27%)
Willingness to repeat  
the procedure
Yes 26 (89%) 23 (79%) 0.094
no 3 (10%) 6 (20%)
Table 2 Adverse events in patients in the direct and indirect 
monitoring groups
Characteristics Direct  
group (%)
Indirect  
group (%)
P value
Sore throat 7 (24.13%) 12 (41.37%) 0.13
Dysphagia 9 (31.03%) 8 (27.58%) 0.77
Chest pain 6 (20.68%) 7 (24.13%) 0.75
Cough 4 (13.79%) 2 (6.89%) 0.74
Procedural complication 2 (6.89%) 1 (3.44%) 0.5
Patients (n) needing days  
off work 
6 (20.68%)  6 (20.68%) 1Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
150
Sofi et al
Discussion
The wireless esophageal pH monitoring system is a highly 
tolerable method of investigation available for patients 
with GERD. Since the introduction of this technology in 
the 2001,7 several methods of placement of the capsule in 
the esophagus have been described. These methods include 
calculating the site of placement of the device by endoscopy, 
followed by either transoral4 or transnasal8 insertion of the 
capsule delivery system, then placing the device at the site 
determined by prior calculation. Deployment of the device 
under direct endoscopic view has also been described.5 In 
addition, nonendoscopic methods of placing the device 
have been described.9 In the nonendoscopic technique of 
device placement, the position of the lower esophageal 
sphincter is determined by esophageal manometry, which 
is then followed by blind deployment of the capsule guided 
by measurements obtained from manometry. However, the 
endoscopic method of placing the capsule is most com-
monly used worldwide. This is because it allows evaluation 
of the upper gastrointestinal tract for the presence of other 
concomitant pathologies that would otherwise preclude the 
use of these devices.10 Furthermore, it allows evaluation of 
the esophagus in patients with GERD. Some authors have 
suggested using the manometry method in patients who had 
recent endoscopy without any alarm signs.10 This technique 
could be potentially useful in patients with long-segment 
Barrett’s esophagus where the squamocolumnar junction is 
no longer the landmark of the lower esophageal sphincter.11 
However, this technique involves placing the capsule by the 
transnasal route, which is not well tolerated by patients and 
poses a risk of significant epistaxis. Using the transoral route 
for placing the device requires usage of a conversion factor 
proposed by Lacy et al.6 However, this conversion factor has 
its own limitations; it cannot be used in patients with a hiatal 
hernia or in patients who are very tall or very short. In view 
of all these limitations, the endoscopic method of placing the 
device is currently the most commonly used method.
There have been no studies to date comparing the direct 
and indirect methods of Bravo capsule placement in the 
esophagus. Currently, the indirect method is most commonly 
used for deploying the device in the lower esophagus.
Sore throat was the most common adverse effect reported 
by our patients (32.7%). Postprocedure dysphagia was the 
second most common adverse event encountered in our 
patients (29.3% of cases). This was comparable with the 
incidence of dysphagia reported in other studies.6 Chest pain 
was seen in 22.4% of cases. Chest pain was predominantly 
reported by patients who complained of dysphagia. 
Inadequate data reception in five patients (three in the indirect 
group and two in the direct group) could have potentially 
occurred due to technical malfunctions with the device, as 
reported in earlier studies.4,6
In theory, the direct method of placing the device would 
be expected to take less time than the conventional method 
because the latter technique usually requires repeat endo-
scopic intubation. However, in our study, we found that the 
average time taken for the procedure was similar between the 
two groups. This can be explained by the fact that endosco-
pists have more experience with the indirect method because 
it has been used since the introduction of this technology, 
whereas the direct method of placement was recently started 
in our hospital. Furthermore, there was no difference in time 
taken in the procedures performed in the morning compared 
with procedures performed in the afternoon (Table 4).
In our study, we found that placing the Bravo capsule 
system under direct visualization is a safe procedure. 
The safety of this method is comparable with the indirect 
method given the similar frequency of procedure-related 
complications seen in the two groups. In addition, the 
added advantage with the direct method is the avoidance of 
second-look endoscopy to confirm the site of attachment of 
the device. The placement of the device by the direct method 
is precise. This is vital because the device could be wrongly 
deployed at an undesirable location, including the stomach 
wall9 or oropharynx,12 by the indirect method. Therefore, 
there would be a remote chance of deploying the capsule at 
an undesirable location with the direct method. Further, the 
direct method of placing the capsule allows the esophagus 
to be cleared of air under direct vision, which ensures the 
successful placement of the device by enhancing the contact 
between the esophageal wall and the well of the capsule. 
This is important because early detachment is a well known 
complication with the Bravo system, and its incidence could 
be as high as 2%–12%.4,13
Table 4 Mean time taken for the direct and indirect method of 
capsule placement
Direct Indirect P value
Morning:afternoon procedures (n) 18:11 22:7
Average time period for procedure  
(minutes) 
14.44 13.31 0.122
Average time period for morning  
procedure (minutes)
14.58 13.46 0.662
Average time period for afternoon  
procedure (minutes)
14.14 13.00 0.303Clinical and Experimental Gastroenterology
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In our study, we found that patient experience with the 
procedure was similar (75.9% versus 66.06%, respectively) 
in the direct group and indirect group. Patient satisfaction 
with the test was similar (34.4% versus 27.5%) between 
the direct and indirect groups. Patient willingness to repeat 
the test, if necessary, was also similar between the two 
groups (89.7% versus 75.5%). The explanation for the small 
observed difference, although not statistically significant, 
could be the fact that in the “indirect” group patients had 
to undergo endoscopy twice in the same sitting. This could 
be more uncomfortable than undergoing single endoscopy. 
For the endoscopist, the direct method may be preferable 
because it avoids performing endoscopy twice in the same 
patient.
Our study had a few limitations. Firstly, it is retrospective 
by design. Secondly, the small sample size of the study 
groups cannot rule out the possibility of Type II error with 
regard to safety and patient experience with the procedure. 
Nonetheless, the results of this study suggest an advantage 
of the direct method over the conventional (indirect) method 
of placement of Bravo capsule system.
Conclusion
The direct method of deploying the wireless pH monitoring 
device is safe and effective. Patient tolerance, acceptance, 
and the length of procedure time were similar to that of the 
indirect method. There is an additional advantage of avoiding 
a second endoscopy in the direct group, although there is 
no difference in the length of procedure time between these 
two techniques. However, a larger prospective study is 
needed to provide more information regarding complications 
and adverse events with these two methods of capsule 
placement.
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